{"pageContent": "Although current guidelines do not endorse the use of primary androgen deprivation therapy (PADT) as monotherapy for localized prostate cancer, many patients continue to receive this treatment. New outcomes research confirms that there is no clear reason for use of PADT in men with localized prostate cancer.", "metaData": {"source": "Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations\nhttps://pubmed.ncbi.nlm.nih.gov/33433743/"}}